Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies

Abstract

The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi‐center, randomized, double‐blind, placebo‐controlled phase III trials; one enrolled patients aged 7–17 years (SIGN 1 trial) and the other enrolled younger patients aged 2–6 years (SIGN 2). In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6‐month double‐blind treatment period. The primary endpoint was change in Childhood Autism Rating Scale 2 (CARS2) total raw score from baseline to Week 26. Key secondary endpoints included changes in Social Responsiveness Scale‐2, Clinical Global Impression Scale, and Vineland Adaptive Behavior Scale. Each study enrolled 211 patients (bumetanide, n = 107; placebo, n = 104). Both studies were terminated early due to absence of any significant difference between bumetanide and placebo in the overall studied populations. In both studies, CARS2 total raw score decreased from baseline to Week 26 in the bumetanide and placebo groups, with no statistically significant difference between groups. No differences were observed between treatment groups for any of the secondary efficacy endpoints in either study. In both studies, treatment‐emergent adverse events that occurred more frequently with bumetanide than placebo included thirst, polyuria, hypokalemia, and dry mouth. These large phase III trials failed to demonstrate a benefit of bumetanide for the treatment of pediatric ASD compared with placebo. Consequently, the sponsor has discontinued the development of bumetanide for the treatment of this condition.Trial registration: https://clinicaltrials.gov: SIGN 1: NCT03715166; SIGN 2: NCT03715153.

TMAO miscompartmentalization is a reversible driver of autism pathophysiology

“…Interestingly, urea is not the first diuretic to be tested in ASD. The loop diuretic bumetanide has shown promising results 45,46 for the treatment of ASD, although a recent phase III clinical trial failed to show efficacy 47 . Loop diuretics provoke the elimination of water and salts, with water loss exceeding that of salt, only resulting in moderate hemoconcentration.…”

Bumetanide to treat autism spectrum disorders: are complex administrative regulations fit to treat heterogeneous disorders?

“…These results suggested that it is worth pursuing this to a Phase 3 development aimed at obtaining market authorization. To align with the requirements of the European Medicine Agency (EMA), this included the entire pediatric population in two separate trials (2-7 and 7-18 years old) [55] . Participants received a bumetanide syrup with a taste agreeable to children /adolescents.…”

Efficacy of bumetanide in animal models of ischemic stroke: a systematic review and meta-analysis

“…Other studies have shown that bumetanide can reduce cerebral edema and nerve cell injury in rats with focal ischemia-reperfusion injury [16][17][18]. Several clinical studies have been conducted to evaluate the efficacy of bumetanide for spectrum disorder (ASD), Parkinson's disease (PD), and neonatal seizures [19][20][21]. Unfortunately, the results were negative.…”